ArticleInternational journal of molecular sciences2026
Red Ginseng Ethanolic Extract Alleviates DSS-Induced Colitis in Mice by Suppressing Inflammatory Mediator Production.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Therapeutic potential of ginseng and its bioactive compounds in inflammatory bowel disease: current evidence and future directions.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by recurrent intestinal inflammation and mucosal injury. This study evaluated the protective potential of red ginseng ethanolic extract (RGEE) using a dextran sulfate sodium (DSS)-induced colitis mouse model and an LPS-stimulated RAW 264.7 macrophage model. Preliminary LC-MS profiling was also performed to characterize the detectable chemical features of RGEE. In vivo, RGEE alleviated DSS-induced body weight loss, disease activity, colon shortening, spleen enlargement, and histopathological injury, with the histopathological score reduced by approximately 51.1%. RGEE also partially improved DSS-induced hematological alterations without causing obvious changes in major organ weights. In vitro, RGEE showed no obvious cytotoxicity up to 250 μg/mL and reduced LPS-induced NO, TNF-α, IL-6, and IL-1β production by approximately 60.0-67.1%. LC-MS analysis putatively annotated several saponin-related features, including notoginsenoside R1 and ginsenosides Rb1, Rb2, Rh1, Rh4, and Rh2. These findings suggest that RGEE has protective potential against DSS-induced colitis, which is associated with the suppression of inflammatory mediator production. Further studies are needed to clarify its active constituents and mechanisms of action.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.